The present invention relates to pharmaceutical compositions comprising MBL and/or MBL variants. In particular the invention relates to pharmaceutical compositions comprising at least 200 .mu.g/ml protein containing material, wherein mannan binding lectin (MBL) and/or MBL variants constitutes at least 35% (w/w) of the total protein; or to compositions comprising at least 400 .mu.g/ml mannan binding lectin (MBL) and/or MBL variants. In addition the invention relates to pharmaceutical compositions comprising MBL and/or MBL variants and divalent cations. The invention also describes methods of preparing said compositions.The pharmaceutical compositions according to the invention may for example be used in methods of treatment of a number of different clinical conditions including infections. Uses of the compositions for preparation of medicaments for treatment of a clinical condition are also described.